Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Plos One
|
October 5, 2018
Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir
Gretja Schnell, Preethi Krishnan, Rakesh Tripathi, et al.
Journal of Hepatology
|
February 27, 2013
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
Eric Lawitz, Fred Poordad, Kris V Kowdley, et al.
The New England Journal of Medicine
|
January 4, 2013
Exploratory study of oral combination antiviral therapy for hepatitis C
Fred Poordad, Eric Lawitz, Kris V Kowdley, et al.
Analytical Biochemistry
|
July 24, 2007
Longer wavelength fluorescence resonance energy transfer depsipeptide substrates for hepatitis C virus NS3 protease
Alex K Konstantinidis, Paul L Richardson, Kevin A Kurtz, et al.
Antimicrobial Agents and Chemotherapy
|
August 1, 2018
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
Preethi Krishnan, Tami Pilot-Matias, Gretja Schnell, et al.
Genome Medicine
|
March 22, 2024
Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences
Justin E Ideozu, Mengzhen Liu, Bridget M Riley-Gillis, et al.
Antimicrobial Agents and Chemotherapy
|
December 9, 2015
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir
Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.
Antimicrobial Agents and Chemotherapy
|
November 29, 2017
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan
Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.
Journal of Medical Virology
|
August 27, 2017
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir
Gretja Schnell, Rakesh Tripathi, Preethi Krishnan, et al.
Antimicrobial Agents and Chemotherapy
|
February 15, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
Teresa I Ng, Preethi Krishnan, Tami Pilot-Matias, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Plos One
|
October 5, 2018
Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir
Gretja Schnell, Preethi Krishnan, Rakesh Tripathi, et al.
Journal of Hepatology
|
February 27, 2013
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
Eric Lawitz, Fred Poordad, Kris V Kowdley, et al.
The New England Journal of Medicine
|
January 4, 2013
Exploratory study of oral combination antiviral therapy for hepatitis C
Fred Poordad, Eric Lawitz, Kris V Kowdley, et al.
Analytical Biochemistry
|
July 24, 2007
Longer wavelength fluorescence resonance energy transfer depsipeptide substrates for hepatitis C virus NS3 protease
Alex K Konstantinidis, Paul L Richardson, Kevin A Kurtz, et al.
Antimicrobial Agents and Chemotherapy
|
August 1, 2018
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
Preethi Krishnan, Tami Pilot-Matias, Gretja Schnell, et al.
Genome Medicine
|
March 22, 2024
Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences
Justin E Ideozu, Mengzhen Liu, Bridget M Riley-Gillis, et al.
Antimicrobial Agents and Chemotherapy
|
December 9, 2015
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir
Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.
Antimicrobial Agents and Chemotherapy
|
November 29, 2017
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan
Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.
Journal of Medical Virology
|
August 27, 2017
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir
Gretja Schnell, Rakesh Tripathi, Preethi Krishnan, et al.
Antimicrobial Agents and Chemotherapy
|
February 15, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
Teresa I Ng, Preethi Krishnan, Tami Pilot-Matias, et al.
Page
of 3